Drug Trial Radar · NCT00630110
Phase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Aug 16, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
172
Actual
Start
Feb 2008
Primary completion
Jun 2011
Study completion Jun 2011
Sponsor
- Lead sponsor
- Nereus Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 6, 2008
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a clinical trial examining the vascular disrupting agent NPI-2358 combined with docetaxel in patients with advanced non-small cell lung cancer (NSCLC). The formation of new blood vessels (angiogenesis) is an important component of tumor growth, vascular disrupting agents are intended to target the differences between these tumor blood vessels and the blood vessels in normal tissues.
Conditions
- Cancer
Interventions
docetaxelDrug
docetaxel (75 mg/m2)
NPI-2358 + docetaxelDrug
NPI-2358 (30 mg/m2) + docetaxel (75 mg/m2)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Compare overall survival of patients treated with docetaxel to patients treated with docetaxel + NPI-2358Time frame: Continuous
Locations
36 sites in 6 countries. Site status is shown where the registry gives one.
Mayo Clinic
Scottsdale, Arizona
San Diego Pacific Oncology & Hematology Associates
Encinitas, California
University San Diego Moores Cancer Center
San Diego, California
Kaiser Permanente
San Diego, California
Premiere Oncology
Santa Monica, California
Massachusetts General Hospital
Boston, Massachusetts
Karmanos Cancer Institute
Detroit, Michigan
University Texas Health Science Center at San Antonio (CTRC)
San Antonio, Texas
Policlinica Privada Instituto de Medicina Nuclear
Bahía Blanca, Argentina
Hospital Britanico
Capital Federal, Argentina
Instituto Oncologico De Cordoba
Córdoba, Argentina
Clinica Universitaria Privada Reina Fabiola
Córdoba, Argentina
Caici Centro de Asistencia e Investigacion Clinica Integral
Rosario, Argentina
Hospital del Centrenario
Rosario, Argentina
Mater Adult Hospital
South Brisbane, Queensland, Australia
Bendigo Health Care Group
Bendigo, Victoria, Australia
Sir Charles Gairdner Hospital
Nedlands, Western Australia, Australia
Fundacap Pip XII Hospital do Cancer de Barretos
Barretos, Brazil
Hospital Erasto Gaertner Liga do Combate as Cancer
Curitiba, Brazil
Associacao Hospital de Caridade Ijui
Ijuí, Brazil
Hospital Sao Lucas
Porte Alegre, Brazil
Hospital de clinicas de Porto Alegre
Porto Alegre, Brazil
Clinionco-Clinica de Oncologia de Porto Alegre
Porto Alegre, Brazil
Hosp.das Clinicas da Univ.de Sao Paulo
São Paulo, Brazil
Instituto do Cancer Aenaldo Vieira de Carvahlo
São Paulo, Brazil
Instituto Nacional del Cancer Oncology
Santiago, Chile
Hospital Carlos Van Buren
Valparaíso, Chile
Kidwai Memorial Institute of Oncology
Bangalore, India
Apollo Speciality Hospital
Chennai, India
Apollo Hospital
Hyderabad, India
SEAROC Cancer Centre S.K. Soni Hospital
Jaipur, India
Subodh Mitra Cancer Hospital & Research Centre
Kolkata, India
Tata Memorial Hospital
Mumbai, India
Ruby Hall Clinic
Pune, India
Andhra Medical College
Visakhapatnam, India
Chittaranjan National Cancer Institute
Kolkata, West Bengal, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.